Navigation Links
TPI to Host Third Quarter Fiscal Year 2013 Earnings Conference Call on Wednesday, May 15, 2013 at 9 a.m. ET
Date:5/5/2013

CHENGDU, China, May 5, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the third quarter of fiscal year 2013 ending March 31, 2013 to be held at 9:00 a.m. ET on Wednesday, May 15th, 2013.

Interested parties may access the call by dialingToll free:

1-877-941-1427International: 

1-480-629-9664The conference ID is 4617492. It is advisable to dial in approximately 5 minutes prior to the start of the call.

A replay will be available by calling

Toll free:

1-877-870-5176International:

1-858-384-5517From:

05/15/13 @ 12:00 pm E.T.To:

05/29/13 @ 11:59 pm E.T.Replay Pin Number:

4617492This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://public.viavid.com/index.php?id=104577

About TPIHeadquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list (EDL) of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit: http://www.tianyinpharma.com

Safe Harbor StatementThe Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email: ir@tpi.asia

Tel:
+86-28-8551-6696 (Chengdu, China)
+86-134-3655-0011 (China)

Address:

Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardica Announces Fiscal 2013 Third Quarter Financial Results
2. Hill-Rom Reports Fiscal Second Quarter Adjusted Earnings Per Share In Line With Expectations; Provides Third Quarter And Updated Full-Year Financial Outlook
3. Perrigo Company To Release Third Quarter Fiscal Year 2013 Results On May 7, 2013
4. Freudenberg Reports Third Year of Sales Growth in 2012
5. Accuray Incorporated to Report Financial Results for Third Quarter Fiscal 2013
6. Cardica to Announce Fiscal 2013 Third Quarter Financial Results On Tuesday, April 30, 2013
7. CareFusion to Report Third Quarter Fiscal 2013 Results on May 9
8. Cardinal Health To Release Third-Quarter Results For Fiscal Year 2013 On May 2
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2013 Results
11. Third FDA Clearance for Revolutionary Simbionix Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017 Summary ... understand Bayer and its partnering interests and activities since 2010. ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ... The report will be delivered in PDF format ...
(Date:3/27/2017)... , March 27, 2017  Cryoport, Inc. (NASDAQ: ... it intends to offer shares of common stock in ... statement on file with the Securities and Exchange Commission ... other conditions, and there can be no assurance as ... or as to the actual size or terms of ...
(Date:3/27/2017)... new survey from the American Association of ... (CBP) significantly reduced beneficiary choice and access to commonly ... beneficiaries to switch to unfamiliar or unsuitable testing systems, ... AADE,s survey is the latest in a continuous round ... inherent problems with the CBP. Last year, a National ...
Breaking Medicine Technology:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... today announced it will co-exhibit with technology partners LG Business Solutions at ... Marriott Metro Center in Washington D.C., will provide education and examination into the ...
(Date:3/27/2017)... ... 2017 , ... M&S Technologies, the first name in computerized ... System® 20/20. CE Certification builds upon M&S's long-standing commitment to products and software ... ISO and proven test methods used in the field of Vision Care. Smart ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may be ... groin injury, it occurs when the muscles around the pelvis become inflamed. Over ... the lower torso, as well as accompanying tenderness and weakness. Without proper intervention, ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... epigenetic research products enables researchers to pursue the recent RNA methylation “gold rush” ... . In light of the newfound characteristics of N6-methyladenosine, or m6A , ...
(Date:3/27/2017)... ... ... Schloz is still in shock after receiving a $2,500 Academic Award from California Casualty ... said. , She thinks the coming week is going to be a very joyful for ... help my students.” , The award will allow the 4th grade teacher at Tumwater Hill ...
Breaking Medicine News(10 mins):